Addison Advisors LLC Raises Stock Position in Johnson & Johnson $JNJ

Addison Advisors LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 10.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,791 shares of the company’s stock after buying an additional 955 shares during the period. Addison Advisors LLC’s holdings in Johnson & Johnson were worth $1,496,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. BOK Financial Private Wealth Inc. increased its stake in Johnson & Johnson by 51.2% in the second quarter. BOK Financial Private Wealth Inc. now owns 13,165 shares of the company’s stock valued at $2,011,000 after purchasing an additional 4,457 shares during the period. Altman Advisors Inc. increased its position in Johnson & Johnson by 2.6% in the 2nd quarter. Altman Advisors Inc. now owns 10,619 shares of the company’s stock valued at $1,656,000 after acquiring an additional 268 shares during the period. Compass Capital Management Inc. raised its stake in Johnson & Johnson by 0.4% during the 2nd quarter. Compass Capital Management Inc. now owns 373,144 shares of the company’s stock valued at $56,998,000 after acquiring an additional 1,511 shares during the last quarter. Fidelis Capital Partners LLC lifted its position in Johnson & Johnson by 0.4% during the 2nd quarter. Fidelis Capital Partners LLC now owns 32,731 shares of the company’s stock worth $5,000,000 after acquiring an additional 122 shares during the period. Finally, Summit X LLC grew its stake in shares of Johnson & Johnson by 3.7% in the 2nd quarter. Summit X LLC now owns 5,352 shares of the company’s stock valued at $817,000 after purchasing an additional 190 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on JNJ. HSBC increased their price target on Johnson & Johnson from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Thursday, October 16th. Erste Group Bank upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the company a “hold” rating in a research report on Wednesday, October 22nd. Finally, Piper Sandler reiterated an “overweight” rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $199.05.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ opened at $186.50 on Monday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $194.48. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $449.34 billion, a P/E ratio of 18.00, a PEG ratio of 2.19 and a beta of 0.38. The firm’s 50-day moving average is $184.25 and its two-hundred day moving average is $168.80.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio is 50.19%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.